Close Menu

Biocept

Ahead of a longer-term goal to develop IVD kits, the company has a plan this year to allow early-access customers to take on one aspect of testing in their own labs.

The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.

Members of the health plan will have access to Biocept's growing menu of circulating tumor cell and circulating tumor DNA tests.

Investigators will compare results using Biocept's platform in cerebrospinal fluid to current standard methods for diagnosing leptomeningeal metastases.

The company said in a filing with the US Securities and Exchange Commission that it failed to maintain compliance with the Nasdaq's minimum closing bid price requirement.

The maker of cancer biomarker assays reported record revenues of more than $1 million in the quarter compared to $164,858 in the prior-year period.

The company sold 9.1 million shares of its common stock and warrants to purchase up to 9.1 million more shares at a combined offering price of $1.10 per share.

The company is offering 9.1 million shares of its common stock, as well as warrants to purchase up to 9.1 million additional shares.

The University of Minnesota's Shilpa Gupta will work with Biocept on a study aimed at providing clinical support for the use of the firm's PD-L1 and AR tests.

Teneovita will distribute Biocept's test services to hospitals, oncology centers, and individual medical practices throughout the country.

Pages

A UK woman is suing three National Health Service Trusts for not telling her about her father's Huntington's disease diagnosis, the BBC reports.

LiveScience reports that a novel mutation in the LPL gene was uncovered in three siblings with very high triglyceride levels.

The president of Nankai University is embroiled in a data manipulation scandal, the South China Morning Post reports.

In PNAS this week: cytotoxic CD4 T cell signature in supercentenarians, evolutionary history of beetles, and more.